# A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct06083207/  
OnCo record `nct06083207` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IBI3003 in multiple myeloma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06083207 by Innovent Biologics (Suzhou) Co. Ltd., with 116 participants planned, started 2024-07-29 and due to reach its primary completion in 2026-10-31. Interventions recorded: IBI3003.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06083207
- Phase: 1/2
- Setting: A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 116

## Sources

- ClinicalTrials.gov NCT06083207: https://clinicaltrials.gov/study/NCT06083207

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)

---
JSON: https://onco.cc/api/v1/entities/nct06083207.json